Ei­sai’s can­cer drug Halaven at the cen­ter of $2B pact with Bliss­Bio, like its Bris­tol My­ers ADC deal

Ei­sai plans to pay up to $2 bil­lion to de­vel­op an an­ti­body-drug con­ju­gate with Chi­nese biotech Bliss Bio­phar­ma­ceu­ti­cal, and the Japan­ese bio­phar­ma could gain ex-Greater Chi­na rights to the ADC, which in­cludes its can­cer med Halaven.

The com­pa­nies said Mon­day that Ei­sai will pay an undis­closed up­front amount to co-de­vel­op BB-1701 through an op­tion pe­ri­od, at which point the duo can form a strate­gic col­lab­o­ra­tion. The ADC us­es Halaven as a pay­load, with the goal of treat­ing breast, lung and oth­er sol­id tu­mors ex­press­ing HER2.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN